The latest price target for Brainstorm Cell (NASDAQ:BCLI) was reported by Maxim Group on July 11, 2024. The analyst firm set a price target for $2.00 expecting BCLI to fall to within 12 months (a possible -18.37% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Brainstorm Cell (NASDAQ:BCLI) was provided by Maxim Group, and Brainstorm Cell upgraded their buy rating.

The last upgrade for Brainstorm Cell Therapeutics Inc happened on July 11, 2024 when Maxim Group raised their price target to $2. Maxim Group previously had a hold for Brainstorm Cell Therapeutics Inc.

The last downgrade for Brainstorm Cell Therapeutics Inc happened on September 28, 2023 when Maxim Group changed their price target from N/A to N/A for Brainstorm Cell Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Brainstorm Cell, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Brainstorm Cell was filed on July 11, 2024 so you should expect the next rating to be made available sometime around July 11, 2025.

While ratings are subjective and will change, the latest Brainstorm Cell (BCLI) rating was a upgraded with a price target of $0.00 to $2.00. The current price Brainstorm Cell (BCLI) is trading at is $2.45, which is out of the analyst’s predicted range.